Amplifica is a preclinical stage biopharmaceutical company dedicated to developing innovative treatments for androgenic alopecia, commonly known as hair loss. The company employs a nature-inspired scientific approach, focusing on a molecular mechanism designed to promote the regrowth of natural hair. Amplifica has successfully identified and isolated unique signaling molecules that stimulate hair follicles, offering healthcare professionals effective solutions for treating hair loss.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
Psudo manufactures sneakers that are locally sourced and built with recycled materials. It also provides antimicrobial, anatomically foot support for all-day wear, enabling customers to get a range of sustainable footwear. The company was founded in 2021 and is based in Saint Louis, Missouri.
Outstanding Foods, Inc. is a Los Angeles-based company that specializes in plant-based vegan snacks. Founded in 2015 and formerly known as Fresh Soul Holdings, Inc., the company rebranded in March 2017. It offers products under the PigOut Rinds and TakeOut Puffs brands, focusing on creating snacks that are both flavorful and made from wholesome ingredients. Renowned vegetarian Chef Dave Anderson employs his proprietary culinary methods to craft these snacks, which include plant-based bacon chips that appeal to those seeking alternatives to traditional bacon. Committed to providing guilt-free indulgence, Outstanding Foods ensures that its products contain no animal-derived ingredients or artificial additives.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”).
Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.
Zoomcar India Private Ltd. is a prominent self-drive car rental service based in Bengaluru, India. Founded in 2012, the company offers a wide range of vehicles, including SUVs, luxury cars, electric cars, and sedans, available for rent by the hour, day, week, or month. Zoomcar operates an online platform that allows customers to easily book cars using their mobile phones, providing a hassle-free rental experience. With approximately 21,000 vehicles registered on its platform, Zoomcar primarily generates revenue from short-term self-drive rentals and vehicle subscriptions, with the majority of its business concentrated in India. The company also has a strategic partnership with Godrej Consumer Products Limited and has expanded its operations to several countries, including Egypt, Indonesia, Vietnam, and the Philippines.
Hydrobuilder.com offers a large selection of indoor grow lights, complete hydroponic system, plant nutrients, ventilation systems, grow tents and more! Hydrobuilder supplies both hobby and commercial cultivators in all 50 states.
Zoomcar India Private Ltd. is a prominent self-drive car rental service based in Bengaluru, India. Founded in 2012, the company offers a wide range of vehicles, including SUVs, luxury cars, electric cars, and sedans, available for rent by the hour, day, week, or month. Zoomcar operates an online platform that allows customers to easily book cars using their mobile phones, providing a hassle-free rental experience. With approximately 21,000 vehicles registered on its platform, Zoomcar primarily generates revenue from short-term self-drive rentals and vehicle subscriptions, with the majority of its business concentrated in India. The company also has a strategic partnership with Godrej Consumer Products Limited and has expanded its operations to several countries, including Egypt, Indonesia, Vietnam, and the Philippines.
Outstanding Foods, Inc. is a Los Angeles-based company that specializes in plant-based vegan snacks. Founded in 2015 and formerly known as Fresh Soul Holdings, Inc., the company rebranded in March 2017. It offers products under the PigOut Rinds and TakeOut Puffs brands, focusing on creating snacks that are both flavorful and made from wholesome ingredients. Renowned vegetarian Chef Dave Anderson employs his proprietary culinary methods to craft these snacks, which include plant-based bacon chips that appeal to those seeking alternatives to traditional bacon. Committed to providing guilt-free indulgence, Outstanding Foods ensures that its products contain no animal-derived ingredients or artificial additives.
DarioHealth Corp. is a digital health company focused on developing and commercializing proprietary technologies that enable consumers to conduct laboratory testing using smartphones and mobile devices. Its primary product, the Dario Smart Diabetes Management Solution, integrates a mobile application with a pocket-sized blood glucose monitoring device. This real-time, cloud-based solution assists users in managing their diabetes by offering features such as monitoring of chronic conditions, coaching, digital communication, and real-time alerts for trends and patterns. DarioHealth markets its products through direct consumer sales, retail pharmacies, hospitals, distributors, and online platforms. The company, originally known as LabStyle Innovations Corp., was founded in 2011 and is headquartered in Caesarea, Israel.
Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.
Outstanding Foods, Inc. is a Los Angeles-based company that specializes in plant-based vegan snacks. Founded in 2015 and formerly known as Fresh Soul Holdings, Inc., the company rebranded in March 2017. It offers products under the PigOut Rinds and TakeOut Puffs brands, focusing on creating snacks that are both flavorful and made from wholesome ingredients. Renowned vegetarian Chef Dave Anderson employs his proprietary culinary methods to craft these snacks, which include plant-based bacon chips that appeal to those seeking alternatives to traditional bacon. Committed to providing guilt-free indulgence, Outstanding Foods ensures that its products contain no animal-derived ingredients or artificial additives.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
DarioHealth Corp. is a digital health company focused on developing and commercializing proprietary technologies that enable consumers to conduct laboratory testing using smartphones and mobile devices. Its primary product, the Dario Smart Diabetes Management Solution, integrates a mobile application with a pocket-sized blood glucose monitoring device. This real-time, cloud-based solution assists users in managing their diabetes by offering features such as monitoring of chronic conditions, coaching, digital communication, and real-time alerts for trends and patterns. DarioHealth markets its products through direct consumer sales, retail pharmacies, hospitals, distributors, and online platforms. The company, originally known as LabStyle Innovations Corp., was founded in 2011 and is headquartered in Caesarea, Israel.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
Hydrofarm is a manufacturer and distributor of controlled environment agriculture equipment and supplies in the United States and Canada. Established in 1977 and headquartered in Petaluma, California, the company specializes in a wide range of products, including lighting systems, hydro components, pumps, irrigation systems, and atmospheric control equipment. Hydrofarm also offers various growing media, such as premium soils and alternatives like rock wool and coconut coir, along with nutrients, food storage products, and consumable supplies. The company markets its products under several brands, including PHOTOBIO, Phantom, and Active Aqua. With over 40 years of experience, Hydrofarm aims to empower growers and cultivators by providing innovative solutions that enhance the quality, efficiency, and productivity of their agricultural endeavors.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
BackBeat Medical Inc. is a medical technology company established in 2010, focusing on innovative cardiac stimulation therapies for hypertension and heart failure. The company has developed a patented treatment called programmable hypertension control (PHC) therapy, which utilizes proprietary pacing algorithms that can be integrated into standard pacemakers. This offers a significant therapeutic alternative for hypertension patients, especially those who already have or need a pacemaker. Clinical results from the Moderato™ pacemaker, which incorporates PHC algorithms, indicate a substantial and sustained reduction in blood pressure, with in-office measurements showing an average decrease of 24 mmHg and 24-hour ambulatory measurements averaging a reduction of 14 mmHg from baseline. The effectiveness of this therapy has been demonstrated in clinical follow-ups extending beyond two years for certain patients. BackBeat Medical's PHC therapy is supported by a comprehensive global patent portfolio, underscoring its commitment to advancing treatment options for hypertension.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Caliber Therapeutics, Inc. engages in the development and commercialization of minimally-invasive balloon-based drug delivery products for the intervention of atherosclerotic diseases. It offers Targeted Angioplasty Drug Delivery balloon, a stent-free delivery platform of anti-restenotic drugs, which enables controlled and targeted drug delivery, reduces thrombosis risk, and reduces the need to implant permanent devices. Caliber Therapeutics, Inc. is based in Monmouth Junction, New Jersey.
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company is based in Fort Lauderdale, Florida.
Helocyte Inc. (“Helocyte”), a portfolio company of Fortress Biotech, is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cytomegalovirus (“CMV”). We aim to: (1) secure rights to new technologies via acquisition, licensing, co-development and/or other partnering; (2) fund research and development of new technologies; and (3) ultimately introduce new technologies to market. We are currently progressing three immunotherapies developed in the laboratory of Donald J. Diamond Ph.D., Chair of the Department of Experimental Therapeutics at City of Hope of Duarte, California (“City of Hope”). In March of 2015, Helocyte consummated an exclusive worldwide license and option agreement with City of Hope, acquiring rights to the current Helocyte programs. PepVax, is an HLA-restricted single antigen [UL83 (pp65)] peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant (“HSCT”) recipients. In July of 2015, we opened a Phase 2 study of PepVax in allogeneic HSCT recipients. Our second program, Triplex, is a universal (non-HLA-restricted) recombinant viral vector vaccine expressing three immuno-dominant proteins [UL83 (pp65), UL123 (IE1), UL122 (IE2)] linked to CMV in the post-transplant setting. In November of 2015, we opened a Phase 2 study of Triplex in allogeneic HSCT recipients. We additionally plan to study Triplex in recipients of allogeneic Solid Organ Transplantation. Our third program, Pentamer, is a universal (non-HLA-restricted) recombinant viral vector vaccine expressing five primary subunits of CMV (gH/gL/UL128/UL130/UL131A) linked to viral transmission in utero. The Pentamer program is currently undergoing nonclinical development and will ultimately be studied for prevention of congenital CMV.
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, specializing in the development and commercialization of therapeutics for rare and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a synthetic oral cannabinoid receptor type 2 (CB2) agonist currently in Phase III trials for systemic sclerosis and dermatomyositis, as well as Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. In addition, Corbus is advancing CRB-4001, a peripherally-restricted cannabinoid receptor type 1 (CB1) inverse agonist, targeting conditions such as nonalcoholic steatohepatitis (NASH). Corbus has established a licensing agreement with Jenrin Discovery, LLC, to develop a library of over 600 compounds, and maintains a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for lenabasum's development in Japan. The company was founded in 2009 and demonstrates a commitment to addressing unmet medical needs in its focused therapeutic areas.
Matinas BioPharma is a clinical-stage biopharmaceutical company based in Bedminster, New Jersey, that specializes in the discovery and development of innovative therapeutics targeting fungal and bacterial infections, as well as cardiovascular and metabolic conditions. Utilizing its proprietary lipid nano-crystal (LNC) delivery platform, the company focuses on orally administered formulations. Its leading product candidates include MAT2203, an oral formulation of amphotericin B currently in Phase II trials for fungal infections, and MAT2501, an encochleated formulation of the antibiotic amikacin, which has completed Phase I trials for multidrug-resistant bacterial infections. Additionally, Matinas is exploring MAT9001, an omega-3 fatty acid formulation for hypertriglyceridemia, and is engaged in research collaborations with organizations like the National Institute of Neurological Disorders and Stroke and ViiV Healthcare to develop antiviral therapies. Founded in 2013, Matinas BioPharma is committed to advancing its product pipeline to address significant unmet medical needs.
Armada Water Assets provides water supply, collection, and remediation services. Armada is a fully integrated service company dedicated to the safe and cost-effective collection, handling, transport, treatment, and reuse of contaminated water produced by conventional oil and gas production (produced water) and hydraulic-fracturing flow-back water. It was founded in 2012 and headquartered in Houston, Texas.
Deem, Inc. is a technology platform based in San Francisco that specializes in solutions for the business travel industry, offering a range of applications for travel, car service, and expense management. Founded in 1999, Deem provides Commerce-as-a-Service (CaaS) to businesses, enabling them to streamline travel bookings and manage expenses efficiently. Its integrated cloud suite allows corporations to control costs, as employees can easily book flights, hotels, and ground transportation, while keeping spending within policy. Additionally, Deem facilitates merchants in promoting their products and services through various consumer engagement strategies, enhancing customer loyalty and broadening market reach. As of January 2019, Deem operates as a subsidiary of Enterprise Holdings, Inc.
DarioHealth Corp. is a digital health company focused on developing and commercializing proprietary technologies that enable consumers to conduct laboratory testing using smartphones and mobile devices. Its primary product, the Dario Smart Diabetes Management Solution, integrates a mobile application with a pocket-sized blood glucose monitoring device. This real-time, cloud-based solution assists users in managing their diabetes by offering features such as monitoring of chronic conditions, coaching, digital communication, and real-time alerts for trends and patterns. DarioHealth markets its products through direct consumer sales, retail pharmacies, hospitals, distributors, and online platforms. The company, originally known as LabStyle Innovations Corp., was founded in 2011 and is headquartered in Caesarea, Israel.
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.
Organovo Holdings, Inc. is a biotechnology company based in Solana Beach, California, specializing in the development of bioprinted human tissues using its innovative 3D human tissue platform technology. This platform features proprietary NovoGen Bioprinters, which create living tissues from mammalian cells, along with technologies for bio-inks and complex multicellular structures. Organovo offers ExVive human liver and kidney tissues, which are utilized for predictive preclinical drug testing. Additionally, the company is working on in vivo liver tissues aimed at treating severe liver diseases and developing NovoTissues liver products using cells from both liver and umbilical cord donors. Founded in 2007, Organovo aims to address unmet medical needs through its advanced tissue engineering capabilities, contributing to the field of regenerative medicine.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.